Article Information
History
- November 4, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Zhen-Yi Andy Ou1,
- Lauren M. Byrne1,
- Filipe B. Rodrigues1,
- Rosanna Tortelli1,
- Eileanoir B. Johnson1,
- Martha S. Foiani2,3,
- Marzena Arridge4,
- Enrico De Vita4,5,
- Rachael I. Scahill1,
- Amanda Heslegrave2,3,
- Henrik Zetterberg2,3,6,7 and
- Edward J. Wild1,*
- 1UCL Huntington’s Disease Centre, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK
- 2UK Dementia Research Institute at UCL, London WC1E 6BT, UK
- 3Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK
- 4Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK
- 5Department of Biomedical Engineering, School of Biomedical Engineering and Imaging Sciences, King’s College London, London SE1 7EH, UK
- 6Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, S-431 80 Mölndal, Sweden
- 7Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80 Mölndal, Sweden
- ↵*Corresponding author; email: e.wild{at}ucl.ac.uk
Posted November 04, 2020.
Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease
